Study on usefulness evaluation of aggressive antihypertensive therapy using ambulatory blood pressure measurement (ABPM)

Study on usefulness evaluation of aggressive antihypertensive therapy using ambulatory blood pressure measurement (ABPM) - INBA Study (Investigation for Normalized Blood pressure control with Appropriate medication)

Status

Unknown

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002071

Enrollment

200

Registered

2009-06-12

Start date

2008-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Patients with essential hypertension, who have been previously treated with antihypertensive drugs including ARB for more than 4 weeks, however, the target blood pressure defined by the guideline for treatment of hypertension has not been achieved 2) Men and women aged 20 to 80 years at the time of the first visit 3) Outpatients 4) Patients who fully understand the study procedures and have given written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1) Patients under treatment with diuretics 2) Patients with uncontrolled hypertension (diastolic blood pressure &#8805;110mmHg) 3) Patients with malignant hypertension 4) Patients with cardiac failure (NYHA grade III or IV) 5) Patients with a previous history of gout attack or uncontrolled hyperuricemia (&#8805;8.0mg/dL) 6) Patients who have stroke, AMI and/or critical vascular complications that required hospitalization within 6 months prior to the intervention 7) Pregnant or breast feeding female patients, including one trying to conceive pregnancy during the planned study period 8) Patients with severe liver dysfunction 9) Patients with renal failure (serum creatinine &#8805;2.0 mg/dL) 10) Patients with a history of hypersensitivity to ingredients of losartan / HCTZ 11) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 12) Patients who are considered not eligible for the study by the attending doctor due to medical reasons

Design outcomes

Primary

Measure	Time frame
Change and % change in ambulatory blood pressure measurement (ABPM) after 12weeks of treatment	—

Secondary

Measure	Time frame
- Change and % change in ABPM after 24 and 48 weeks of treatment - Effect on regression of heart hypertrophy, left ventricular mass index, augmentation index, and laboratory markers (MMP2, MMP9, TIMP, BNP) after 48 weeks of treatment - Change in office blood pressure after 12, 24 and 48 weeks of treatment - Safety throughout the treatment period - Exploratory subgroup analysis	—

Countries

Japan

Contacts

Public ContactChikao Ibuki

Hokuso hypertension study group secretariat Hokuso hypertension study group secretariat

ibuki@nms.ac.jp

Outcome results